Accueil   Diary - News   All news Valneva Raises €50 Million

Valneva Raises €50 Million

 

Saint-Herblain (France), September 27th, 2018 – Valneva SE (“Valneva” or “the Company”), a commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that it has raised €50 million of gross proceeds in a private placement of its ordinary shares. The transaction, led by blue-chip US healthcare investors and supported by the Company’s existing major shareholders, was heavily oversubscribed.

 

Thomas Lingelbach, Valneva’s Chief Executive Officer, commented: “We are delighted that several leading US healthcare funds have invested in Valneva. This investment supports our capital access strategy and future growth, including the acceleration of our key development programs. We are grateful for the continued support of our main existing shareholders”.

 

 

 

Read the press release